
    
      This Phase 2 study examines the efficacy, safety, tolerability, and pharmacokinetics (PK) of
      tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on
      treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable
      curative therapy exists.
    
  